Clinical trials
Follow clinical development from study design and recruitment through results.
- Trial phase
- Status
- Readouts
Drug intelligence / Profile preview
lorcaserin
- Development stage
- Phase 4
- Lead developer
- Pfizer
- Modality
- Small Molecules
- Administration
- Oral, Intravenous
01
Overview
Lorcaserin is a small molecule serotonin 2C receptor agonist developed for chronic weight management in adults who are obese (BMI ≥30 kg/m²) or overweight (BMI ≥27 kg/m²) with at least one weight-related comorbidity such as hypertension, dyslipidemia, or type 2 diabetes. Lorcaserin acts centrally to promote satiety and reduce food intake by selectively activating the serotonin 2C receptor in the brain. It was first approved by the FDA in June 2012 under the brand name Belviq and later as an extended-release formulation (Belviq XR). In February 2020, it was withdrawn from the U.S. market due to an increased risk of cancer observed in long-term clinical trials[1][2][3][5][7][8].
- Brand names
- BelviqBelviq XRVenespri
- Other names
- lorcaserin hydrochloride
02
Targets
HTR2C (5-hydroxytryptamine 2C receptor)
Beyond the preview
Go deeper on lorcaserin.
Explore the evidence, development activity, and competitive landscape with Gosset’s full data platform.
Indications & development
Explore development by indication, patient population, and geography.
- Indications
- Development status
- Countries
Licensing & deals
Trace asset ownership, licensing agreements, and commercial partnerships.
- Partners
- Deal terms
- Milestones
Patents & exclusivity
Explore the patent landscape and regulatory exclusivity around an asset.
- Patents
- Expiration dates
- Exclusivity
Competitive landscape
Compare development programs by target, modality, and indication.
- Competing assets
- Targets
- Development stage
Research & analysis
Connect source evidence and development news to your research questions.
- Publications
- News
- Analysis
Bring the full picture into focus.
See how Gosset can support your research on lorcaserin.